

Christopher A Bishop

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9394659/publications.pdf>

Version: 2024-02-01

59
papers

2,159
citations

186265
28
h-index

233421
45
g-index

59
all docs

59
docs citations

59
times ranked

1699
citing authors

#	ARTICLE	IF	CITATIONS
1	Modulation of nigral dopamine signaling mitigates parkinsonian signs of aging: evidence from intervention with calorie restriction or inhibition of dopamine uptake. <i>GeroScience</i> , 2023, 45, 45-63.	4.6	7
2	The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats. <i>Psychopharmacology</i> , 2022, , 1.	3.1	3
3	The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces L-DOPA-induced dyskinesia in hemiparkinsonian rats. <i>Pharmacology Biochemistry and Behavior</i> , 2022, 217, 173393.	2.9	8
4	Genetic suppression of the dopamine D3 receptor in striatal D1 cells reduces the development of L-DOPA-induced dyskinesia. <i>Experimental Neurology</i> , 2021, 336, 113534.	4.1	13
5	Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats. <i>European Journal of Neuroscience</i> , 2021, 53, 2835-2847.	2.6	7
6	Stereotaxic Intracranial Delivery of Chemicals, Proteins or Viral Vectors to Study Parkinson's Disease. <i>Journal of Visualized Experiments</i> , 2021, , .	0.3	0
7	Genetic basis of susceptibility to low-dose paraquat and variation between the sexes in <i>Drosophila melanogaster</i> . <i>Molecular Ecology</i> , 2021, 30, 2040-2053.	3.9	11
8	Dopamine D3 Receptor Plasticity in Parkinson's Disease and L-DOPA-Induced Dyskinesia. <i>Biomedicines</i> , 2021, 9, 314.	3.2	5
9	Combined Knockout of Lrrk2 and Rab29 Does Not Result in Behavioral Abnormalities in vivo. <i>Journal of Parkinson's Disease</i> , 2021, 11, 569-584.	2.8	7
10	Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat. <i>Psychopharmacology</i> , 2020, 237, 155-165.	3.1	8
11	Dopamine receptor cooperativity synergistically drives dyskinesia, motor behavior, and striatal GABA neurotransmission in hemiparkinsonian rats. <i>Neuropharmacology</i> , 2020, 174, 108138.	4.1	3
12	Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats. <i>Experimental Neurology</i> , 2020, 330, 113327.	4.1	10
13	Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat. <i>Neurobiology of Aging</i> , 2019, 81, 190-199.	3.1	10
14	Effects of Muscarinic Acetylcholine m1 and m4 Receptor Blockade on Dyskinesia in the Hemi-Parkinsonian Rat. <i>Neuroscience</i> , 2019, 409, 180-194.	2.3	38
15	Biased G Protein-Independent Signaling of Dopamine D1-D3 Receptor Heteromers in the Nucleus Accumbens. <i>Molecular Neurobiology</i> , 2019, 56, 6756-6769.	4.0	33
16	Neuroinflammation: Fanning the fire of dopamine-induced dyskinesia. <i>Movement Disorders</i> , 2019, 34, 1758-1760.	3.9	6
17	Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia. <i>Acta Neuropathologica Communications</i> , 2019, 7, 8.	5.2	50
18	Pedunculopontine Nucleus Degeneration Contributes to Both Motor and Non-Motor Symptoms of Parkinson's Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 1494.	3.5	29

#	ARTICLE	IF	CITATIONS
19	Striatal norepinephrine efflux in L-DOPA-induced dyskinesia. <i>Neurochemistry International</i> , 2018, 114, 85-98.	3.8	10
20	Serotonergic targets for the treatment of L-DOPA-induced dyskinesia. <i>Journal of Neural Transmission</i> , 2018, 125, 1203-1216.	2.8	28
21	Diverse serotonin actions of vilazodone reduce 3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian rats. <i>Movement Disorders</i> , 2018, 33, 1740-1749.	3.9	19
22	A new outlook on cholinergic interneurons in Parkinson's disease and L-DOPA-induced dyskinesia. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 92, 67-82.	6.1	31
23	Behavioral and cellular dopamine D1 and D3 receptor-mediated synergy: Implications for L-DOPA-induced dyskinesia. <i>Neuropharmacology</i> , 2018, 138, 304-314.	4.1	34
24	Ceftriaxone reduces L-DOPA-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model. <i>Movement Disorders</i> , 2017, 32, 1547-1556.	3.9	42
25	Characterizing the differential roles of striatal 5-HT 1A auto- and hetero-receptors in the reduction of L-DOPA-induced dyskinesia. <i>Experimental Neurology</i> , 2017, 292, 168-178.	4.1	37
26	D-512, a novel dopamine D _{2/3} receptor agonist, demonstrates greater anti-Parkinsonian efficacy than ropinirole in Parkinsonian rats. <i>British Journal of Pharmacology</i> , 2017, 174, 3058-3071.	5.4	22
27	Monoamine transporter contributions to L-DOPA effects in hemi-parkinsonian rats. <i>Neuropharmacology</i> , 2016, 110, 125-134.	4.1	24
28	The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in L-DOPA-Induced Dyskinesia in Parkinsonian Rats. <i>Journal of Neuroscience</i> , 2016, 36, 9873-9887.	3.6	30
29	Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats. <i>Pharmacology Biochemistry and Behavior</i> , 2016, 142, 64-71.	2.9	20
30	A working model for the assessment of disruptions in social behavior among aged rats: The role of sex differences, social recognition, and sensorimotor processes. <i>Experimental Gerontology</i> , 2016, 76, 46-57.	2.8	20
31	Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemiparkinsonian rat. <i>Journal of Neurochemistry</i> , 2015, 134, 222-232.	3.9	30
32	Modulation of L-DOPA's antiparkinsonian and dyskinesic effects by \pm 2-noradrenergic receptors within the locus coeruleus. <i>Neuropharmacology</i> , 2015, 95, 215-225.	4.1	21
33	Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats. <i>Neuropharmacology</i> , 2014, 77, 1-8.	4.1	57
34	Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsiveness to L-DOPA in the hemi-parkinsonian rat. <i>Behavioural Brain Research</i> , 2014, 270, 75-85.	2.2	22
35	The Role of the Noradrenergic System and Its Receptors in Levodopa-Induced Dyskinesia. , 2014, , 265-283.		0
36	Critical involvement of the motor cortex in the pathophysiology and treatment of Parkinson's disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 2737-2750.	6.1	111

#	ARTICLE	IF	CITATIONS
37	Effects of 5-HT _{1A} Receptor Stimulation on D1 Receptor Agonist-Induced Striatonigral Activity and Dyskinesia in Hemiparkinsonian Rats. <i>ACS Chemical Neuroscience</i> , 2013, 4, 747-760.	3.5	30
38	Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by $\hat{1}$ - and $\hat{2}$ -adrenergic receptor antagonists in hemiparkinsonian rats. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 100, 607-615.	2.9	49
39	Serotonin transporter inhibition attenuates L-DOPA-induced dyskinesia without compromising L-DOPA efficacy in hemiparkinsonian rats. <i>European Journal of Neuroscience</i> , 2012, 36, 2839-2848.	2.6	70
40	Role of the primary motor cortex in L-DOPA-induced dyskinesia and its modulation by 5-HT _{1A} receptor stimulation. <i>Neuropharmacology</i> , 2011, 61, 753-760.	4.1	61
41	Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. <i>Experimental Neurology</i> , 2011, 229, 288-299.	4.1	111
42	Tryptophan hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: possible link to serotonin deficits and non-motor symptoms in Parkinson's disease. <i>Journal of Neurochemistry</i> , 2011, 116, 426-437.	3.9	26
43	Potential mechanisms underlying anxiety and depression in Parkinson's disease: Consequences of L-DOPA treatment. <i>Neuroscience and Biobehavioral Reviews</i> , 2011, 35, 556-564.	6.1	109
44	Behavioral and Cellular Modulation of L-DOPA-Induced Dyskinesia by $\hat{2}$ -Adrenoceptor Blockade in the 6-Hydroxydopamine-Lesioned Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 337, 755-765.	2.5	44
45	Contribution of the striatum to the effects of 5-HT _{1A} receptor stimulation in L-DOPA-treated hemiparkinsonian rats. <i>Journal of Neuroscience Research</i> , 2009, 87, 1645-1658.	2.9	79
46	The role of the dorsal raphe nucleus in the development, expression, and treatment of L-DOPA-induced dyskinesia in hemiparkinsonian rats. <i>Synapse</i> , 2009, 63, 610-620.	1.2	118
47	Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia. <i>NeuroReport</i> , 2009, 20, 1265-1269.	1.2	39
48	Effects of coincident 5-HT _{1A} receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemiparkinsonian rat. <i>Psychopharmacology</i> , 2008, 199, 99-108.	3.1	50
49	Striatal 5-HT _{1A} receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. <i>Neuropharmacology</i> , 2008, 55, 1321-1328.	4.1	80
50	The differential effects of 5-HT _{1A} receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. <i>Brain Research</i> , 2007, 1158, 135-143.	2.2	82
51	The partial 5-HT _{1A} agonist bupirone reduces the expression and development of L-DOPA-induced dyskinesia in rats and improves L-DOPA efficacy. <i>Pharmacology Biochemistry and Behavior</i> , 2007, 87, 306-314.	2.9	136
52	Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat. <i>Neuropharmacology</i> , 2006, 50, 761-768.	4.1	45
53	MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT _{1A} receptor stimulation. <i>European Journal of Neuroscience</i> , 2006, 23, 2669-2676.	2.6	58
54	Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 81, 887-893.	2.9	68

#	ARTICLE	IF	CITATIONS
55	Intrastriatal dopamine D1 receptor agonist-mediated motor behavior is reduced by local neurokinin 1 receptor antagonism. <i>Synapse</i> , 2005, 57, 1-7.	1.2	12
56	Serotonin 5-HT but not 5-HT receptor antagonism reduces hyperlocomotor activity induced in dopamine-depleted rats by striatal administration of the D agonist SKF 82958. <i>Neuropharmacology</i> , 2005, 49, 350-358.	4.1	29
57	Serotonin 5-HT2A Receptors Underlie Increased Motor Behaviors Induced in Dopamine-Depleted Rats by Intrastriatal 5-HT2A/2C Agonism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 687-694.	2.5	48
58	Intranigral antagonism of neurokinin 1 and 3 receptors reduces intrastriatal dopamine D1 receptor-stimulated locomotion in the rat. <i>Brain Research</i> , 2004, 1023, 126-133.	2.2	9
59	Response to Rye and Bliwise. <i>Sleep</i> , 1997, 20, 814-814.	1.1	0